AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Neurobiological Effect of 5-HT2AR Modulation

RecruitingPhase 1Ages 18 Years - anyAllGitte Moos Knudsen
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin). Magnetic resonance imaging (MRI) and positron emission tomography (PET) will be used as neuroimaging tools.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1\) Healthy individuals above 18 years of age. Exclusion Criteria (For Subprojects 1, 2a, 2b, and 3): 1. Presence of or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10 diagnostic classifications) or in first-degree relatives. 2. Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results. 3. Non-fluent Danish language skills. 4. Vision or hearing impairment. 5. Previous or present learning disability. 6. Pregnancy. 7. Breastfeeding. 8. Contraindications in regard to MRI scanning. 9. Alcohol or drug abuse. 10. Allergy to test drugs. 11. Participation in studies in which participant has received more than 10 mSv of radiation or other significant exposure to radiation. 12. Abnormal ECG or intake of QT prolonging medication. 13. Previous significant side-effects in regard to hallucinogenic drugs. 14. Use of hallucinogenic drugs 6 months previous to inclusion. 15. Blood donation 3 months before and after project participation 16. Body weight under 50 kg. 17. Plasma ferritin levels outside normal range Exclusion Criteria (For Subproject 2c): 1. Presence of or previous primary psychiatric disease (DSM IV axis 1 or WHO ICD-10 diagnostic classifications). 2. Presence of or previous primary psychiatric disease with psychosis symptoms or hypomania (DSM IV axis 1 \[drug/alcohol abuse/dependence, schizophrenia and other psychoses\] or WHO ICD-10 diagnostic classifications \[F10-29, as well as F30-39 with psychotic symptoms, F60\]) in first-degree relatives (parents or siblings). 3. Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results. 4. Non-fluent Danish language skills or pronounced vision or hearing impairment. 5. Previous or present learning disability. 6. Pregnancy. 7. Breastfeeding. 8. Contraindications in regard to MRI scanning. 9. Alcohol or drug abuse. 10. Allergy to test drugs. 11. Abnormal ECG or intake of QT prolonging medication. 12. Previous significant side-effects in regard to hallucinogenic drugs. 13. Previous use of hallucinogenic drugs. 14. Body weight under 45 kg. 15. Ethical concerns regarding the administration of a psychedelic drug.
๐Ÿ’Š

What it tests

  • Psilocybine
  • Ketanserin
๐Ÿ“

Where

1 site
Neurobiology Research Unit, Rigshospitalet
Copenhagen, Denmark
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy